LENZ Therapeutics, Inc. (LENZ)
Automate Your Wheel Strategy on LENZ
With Tiblio's Option Bot, you can configure your own wheel strategy including LENZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LENZ
- Rev/Share 0.1804
- Book/Share 7.3494
- PB 5.4222
- Debt/Equity 0.0051
- CurrentRatio 20.5426
- ROIC -0.3016
- MktCap 1136605685.0
- FreeCF/Share -1.7059
- PFCF -23.7282
- PE -21.3548
- Debt/Assets 0.0048
- DivYield 0
- ROE -0.2563
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LENZ | Piper Sandler | -- | Overweight | $38 | $51 | April 14, 2025 |
| Initiation | LENZ | TD Cowen | -- | Buy | -- | $60 | March 18, 2025 |
| Initiation | LENZ | Raymond James | -- | Outperform | -- | $37 | Sept. 27, 2024 |
News
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Negative
LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to a loss of $0.4 per share a year ago.
Read More
LENZ Therapeutics: Undervalued Ahead Of PDUFA
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Positive
LNZ100 shows superior efficacy and safety in presbyopia treatment, with a strong probability of FDA approval by August 2025. LNZ100 outperforms competitors Vuity and Qlosi, offering faster and greater near-vision improvement with a similar safety profile. Financials are solid with $185M cash, and peak sales could reach $500M, supporting a Buy rating despite some market premium.
Read More
LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 30.9% upside potential for LENZ Therapeutics, Inc. (LENZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen Pawan Patel - Bank of America Yigal Nochomovitz - Citi Lachlan Hanbury-Brown - William Blair Denis Reznik - Raymond James Matthew Caufield - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics First Quarter 2025 Financial Results Conference Call.
Read More
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia.
Read More
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in a fireside chat and one-on-one meetings at the BofA Securities 2025 Health Care Conference taking place May 13- 15, 2025 in Las Vegas, NV.
Read More
LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript
Published: March 19, 2025 by: Seeking Alpha
Sentiment: Neutral
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Yennawar - Leerink Partners Joe Catanzaro - Piper Sandler Stacy Ku - TD Cowen Jason Gerberry - Bank of America Lachlan Hanbury-Brown - William Blair Denis Reznik - Raymond James Matthew Caufield - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics Year …
Read More
LENZ Therapeutics to Participate in Upcoming Investor Conferences
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
Read More
About LENZ Therapeutics, Inc. (LENZ)
- IPO Date 2024-03-22
- Website https://www.lenz-tx.com
- Industry Biotechnology
- CEO Evert B. Schimmelpennink
- Employees 6